Literature DB >> 29561205

Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms.

Nathalie Denizon1, Alix Baugier de Materre2, Mustapha Alani1, Habib Ghnaya1, Jonathan Farhi1, Anne Besançon1, Kamel Laribi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29561205     DOI： 10.1080/10428194.2018.1452214

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  1 in total

1.  Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy.

Authors:  Kamel Laribi; Alix Baugier de Materre; David Ghez; Caroline Dartigeas; Cécile Tomowiak; Béatrice Mahé; Jean-Baptiste Micol; Fatiha Merabet; Stéphane Leprêtre; Charles Herbaux; Loïc Ysebaert; Ronan Le Calloch; Lise Willems; Maud Voldoire; Damien Roos-Weil; Clotilde Bravetti; Yamina Touileb; Frédéric Davi; Florence Nguyen-Khac; Karim Maloum; Marie C Béné
Journal:  Hemasphere       Date:  2022-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.